Literature DB >> 23344532

Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival.

Sang Hyun Shin1, Song Cheol Kim, Seung-Mo Hong, Young Hoon Kim, Ki-Byung Song, Kwang-Min Park, Young-Joo Lee.   

Abstract

OBJECTIVES: The objective of this study was to evaluate genetic alterations of K-ras, p53, c-erbB-2, and deleted in pancreatic cancer, locus 4 (DPC4) genes in pancreatic ductal adenocarcinoma and correlate these changes with patients' overall survival.
METHODS: Between April 2004 and December 2008, 272 patients with pancreatic ductal adenocarcinoma underwent surgical resection at a single institute. Genetic analyses and immunohistochemical stains were reviewed retrospectively.
RESULTS: Alterational rates of each gene were as follows: K-ras, 53.8%; p53, 38.2%; c-erbB-2, 7.3%; DPC4, 81.6%. Subtypes of K-ras gene were as follows: GGT (wild type), 46.2%; GAT, 31.2%; GTT, 14.5%; CGT, 5.6%; TGT, 1.7%; CTG, 0.4%; AGT, 0.4%. K-ras mutation (especially GAT subtype) and DPC4 inactivation resulted in a reduction of postresection survival (P = 0.001 and P = 0.047). Univariate analysis revealed 8 factors affecting to the survival, and multivariate analysis revealed that 6 of them were independently responsible for poor survival of patients: presence of lymphovascular tumor emboli, DPC4 inactivation, poorly differentiated carcinoma, K-ras mutation, presence of lymph node metastasis, and elevated CA-19-9 (>37 U/mL).
CONCLUSIONS: This study may help to understand the genetic feature of pancreatic cancer and its survival effect in our population. This shows that additional genetic insights would contribute to the improvement of patients' prognosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23344532     DOI: 10.1097/MPA.0b013e31825b6ab0

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  42 in total

Review 1.  Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts.

Authors:  Stephan Kruger; Michael Haas; Steffen Ormanns; Sibylle Bächmann; Jens T Siveke; Thomas Kirchner; Volker Heinemann; Stefan Boeck
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

2.  Inhibition of SCAMP1 suppresses cell migration and invasion in human pancreatic and gallbladder cancer cells.

Authors:  Sera Yang; Kyu Taek Lee; Jin Young Lee; Jong Kyoon Lee; Kwang Hyuck Lee; Jong Chul Rhee
Journal:  Tumour Biol       Date:  2013-05-08

Review 3.  Systematic review of peri-operative prognostic biomarkers in pancreatic ductal adenocarcinoma.

Authors:  Wilson Petrushnko; Justin S Gundara; Philip R De Reuver; Greg O'Grady; Jaswinder S Samra; Anubhav Mittal
Journal:  HPB (Oxford)       Date:  2016-07-14       Impact factor: 3.647

4.  Detection of K-ras gene mutations in feces by magnetic nanoprobe in patients with pancreatic cancer: A preliminary study.

Authors:  Xiaoguang Wang; Jingshuai Wang; Fei Chen; Zhengxiang Zhong; Lifeng Qi
Journal:  Exp Ther Med       Date:  2017-10-24       Impact factor: 2.447

5.  DPC4 gene expression in primary pancreatic ductal adenocarcinoma: relationship with CT characteristics.

Authors:  Sang Hyun Choi; Hyoung Jung Kim; Kyung Won Kim; Soyeon An; Seung-Mo Hong; Song Cheol Kim; Myung-Hwan Kim
Journal:  Br J Radiol       Date:  2017-03-24       Impact factor: 3.039

6.  MicroRNAs in stool samples as potential screening biomarkers for pancreatic ductal adenocarcinoma cancer.

Authors:  Jian-Yu Yang; Yong-Wei Sun; De-Jun Liu; Jun-Feng Zhang; Jiao Li; Rong Hua
Journal:  Am J Cancer Res       Date:  2014-11-19       Impact factor: 6.166

7.  Impact of p53 and PDGFR-β Expression on Metastasis and Prognosis of Patients with Pancreatic Cancer.

Authors:  Hiroshi Kurahara; Kosei Maemura; Yuko Mataki; Masahiko Sakoda; Hiroyuki Shinchi; Shoji Natsugoe
Journal:  World J Surg       Date:  2016-08       Impact factor: 3.352

Review 8.  K-Ras mutation detection in liquid biopsy and tumor tissue as prognostic biomarker in patients with pancreatic cancer: a systematic review with meta-analysis.

Authors:  Tao Li; Yuanting Zheng; Hong Sun; Rongyuan Zhuang; Jing Liu; Tianshu Liu; Weimin Cai
Journal:  Med Oncol       Date:  2016-05-25       Impact factor: 3.064

Review 9.  Biomarkers for pancreatic cancer: promising new markers and options beyond CA 19-9.

Authors:  Umashankar K Ballehaninna; Ronald S Chamberlain
Journal:  Tumour Biol       Date:  2013-08-17

Review 10.  KRAS mutation in pancreatic cancer.

Authors:  Ji Luo
Journal:  Semin Oncol       Date:  2021-02-23       Impact factor: 4.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.